Phathom Pharmaceuticals (PHAT) Change in Accured Expenses (2018 - 2026)

Phathom Pharmaceuticals (PHAT) has 9 years of Change in Accured Expenses data on file, last reported at -$3.1 million in Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 3495.65% year-over-year to -$3.1 million in Q1 2026; TTM through Mar 2026 was -$3.1 million, a 108.88% decrease from a year earlier, with the FY2025 full-year figure at $121000.0, down 99.65% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$3.1 million, up from -$6.4 million in the prior quarter.
• Over the last five years, Change in Accured Expenses for PHAT reached as high as $34.6 million in Q4 2024 and fell as low as -$6.4 million in Q4 2025.
• Historically, Change in Accured Expenses has averaged $2.3 million across 5 years, with a median of $92000.0 in 2025.
• Across the five-year window, Change in Accured Expenses soared 28710.0% in 2022 and slumped 11096.67% in 2024, its largest moves.
• Year by year, Change in Accured Expenses stood at $168000.0 in 2022, then surged by 3654.17% to $6.3 million in 2023, then jumped by 447.96% to $34.6 million in 2024, then sank by 118.54% to -$6.4 million in 2025, then soared by 51.26% to -$3.1 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were -$3.1 million in Q1 2026, -$6.4 million in Q4 2025, and $1.1 million in Q3 2025.